Australian Shares Rise on Tech Rally; Telix Faces US FDA Setback

MT Newswires Live
Yesterday

Australian shares continued to rally on Monday, led by the information technology sector, with all but one sector trading in the green.

The S&P/ASX 200 Index rose 28.90 points, or 0.36%, to 7,997.10.

The information technology sector climbed 1.4% in trading on Monday, benefiting from a strong showing by the tech-heavy Nasdaq on Friday.

On the domestic front, business conditions and confidence among Australia's small and medium-sized enterprises improved in the first quarter, according to a survey by National Australia Bank. The business conditions index improved 3 points to negative 1 index points. The business confidence measure improved 4 points to negative 8 index points.

The Reserve Bank of Australia is all set to cut the interest rate in May, regardless of first-quarter inflation data due on Wednesday, Westpac said. It added that, "The turmoil abroad has...changed the game and flipped the risks."

The sustainable finance sector in Australia and New Zealand is in the early stages of development, and a combination of market drivers and global regulatory changes is likely to support its growth trajectory, Fitch Ratings said.

In company news, Telix Pharmaceuticals (ASX:TLX) said the US Food and Drug Administration (FDA) ruled that its New Drug Application for TLX101-CDx, an investigational agent for the imaging of glioma, cannot be approved in its current form. Its shares fell over 6% on market close.

ASX (ASX:ASX) is set to launch a review of its listing rules, including whether companies should disclose if they have secured a waiver to the rules, after backlash to its decision to allow James Hardie Industries (ASX:JHX) to proceed with a significant merger without a shareholder vote, The Australian Financial Review reported. Despite the decision to review the rules, James Hardie will be allowed to proceed with its transaction, per the report.

Domain Holdings Australia (ASX:DHG) said the initial exclusivity period granted to CoStar Group to undertake due diligence for its non-binding indicative acquisition proposal has been extended by two weeks to May 12.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10